Drugs / Bacille Calmette Guérin
Bacille Calmette Guérin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07094711 Comparator | Apr 2026 → Sep 2028 expected | Mycobacterium avium complex disease | University of Virginia | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacille Calmette Guérin | “Bacille Calmette Guérin (BCG) and new TB vaccines: Specific, cross-mycobacterial and off-target effects.” PMID 32958428 ↗ Aug 2020 |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07094711 ↗ |
| Known as | Mycobacterium bovis Bacillus Calmette Guerin | “Biological/Vaccine: Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine” NCT07094711 ↗ |
| Known as | TICE BCG | “TICE® BCG” NCT07094711 ↗ |
| Modality | Vaccine | “BCG vaccine” NCT07094711 ↗ |